Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INV-101 · 1 trial · 1 indication
Cmax following single dose
AUC following single dose
Half-live following single dose
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 20 mg INV-101 |
| Cohort 2 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 80 mg INV-101 |
| Cohort 3 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 160 mg INV-101 |
| Cohort 4 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 320 mg INV-101 |
| Cohort 5 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 500 mg INV-101 |
| Name | Type | Description |
|---|---|---|
| INV-101 | DRUG | Subjects will be randomized to receive INV-101 tablets |
| Placebo | DRUG | Subjects will be randomized to receive placebo tablets |
Inclusion Criteria: * Healthy adult male or female * Body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively; and body weight ≥60 kg * Non- or ex-smoker * Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physica...
INV-101 is an investigational small molecule developed by Novo Nordisk A/S. It has been studied in a Phase 1 clinical trial evaluating its safety, tolerability, and pharmacokinetics in healthy adult volunteers. The specific disease or condition INV-101 is intended to treat has not been disclosed.
INV-101 is being developed by Novo Nordisk A/S, which trades on the New York Stock Exchange under the ticker NVO. Novo Nordisk is the sponsor of the clinical program for this investigational small molecule.
INV-101 is in Phase 1 clinical development. Its single recorded trial, NCT04531150, has been completed. The study was a Phase 1 trial, and no later-stage trials have been registered, so INV-101 remains an investigational drug rather than an approved therapy.
INV-101 has been studied in one clinical trial, NCT04531150, titled "Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects." The Phase 1 trial enrolled 40 healthy volunteers in Canada and is now completed.
The INV-101 Phase 1 trial, NCT04531150, was a randomized, double-blind, controlled study of single ascending oral doses in healthy male and female subjects. It enrolled 40 participants at sites in Canada, included subjects aged 15 years and older, and has been completed.